IMUX
Immunic, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Neutral
-20/100
Last price
8.19
▲ 0.12 (1.49%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
8.19
Prev close
8.07
Day high
8.17
Day low
7.77
Volume
347.79K
Market cap
$106.70M
P/E (TTM)
—
52W range
5.06 – 17.43
Day trading desk
Gap from prior close
+1.49%
Prior close 8.07
VWAP
—
—
Relative volume
0.00×
Quiet session
Session range
—
8.19 – 8.19
Position in range
—
—
ATR (14D)
0.70
8.54% of price
Prior day high
8.17
PDH
Prior day low
7.70
PDL
Bid / ask spread
—
Quote not published
Session volume
—
Avg 272.20K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-12.23%
-14.2%
1M
-40.35%
-41.5%
3M
-47.05%
-51.6%
6M
-34.29%
-52.5%
YTD
+46.44%
+32.2%
1Y
-20.04%
-36.5%
3Y
-46.80%
-129.1%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on IMUX open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
-11.14M
Net selling
Buy transactions
28
650.55K shares
Sell transactions
10
11.79M shares
Net transactions
+38
Buys less sells
Sell : buy shares
18.1 : 1
Heavily one-sided
Insider-held shares
132.49K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jun 13, 25 | NASH DUANE D Officer and Director |
BUY | 20.00K | $16.69K | Direct |
| Jun 5, 25 | NEERMANN JOERG Director |
BUY | 100.00K | $76.70K | Direct |
| Jun 5, 25 | TARDIO JASON President |
BUY | 12.51K | $9.88K | Direct |
| Jun 5, 25 | TARDIO JASON President |
BUY | 12.51K | $9.88K | Direct |
| Jun 4, 25 | VITT DANIEL Chief Executive Officer |
BUY | 15.00K | $11.55K | Direct |
| Jun 4, 25 | VITT DANIEL Officer and Director |
BUY | 15.00K | $11.55K | Direct |
| Jun 3, 25 | WHALEY GLENN Chief Financial Officer |
BUY | 45.00K | $32.08K | Direct |
| Jun 3, 25 | RUDICK RICHARD ALAN Director |
BUY | 143.07K | $100.02K | Direct |
| May 30, 25 | WHALEY GLENN Chief Financial Officer |
STOCK | 25.00K | $14.00K | Direct |
| Nov 12, 24 | RUDICK RICHARD ALAN Director |
BUY | 87.30K | $100.37K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
NASH DUANE D |
Officer and Director | 36.03K | Purchase |
NEERMANN JOERG |
Director | 200.00K | Purchase |
RUDICK RICHARD ALAN |
Director | 230.38K | Purchase |
TARDIO JASON |
President | 12.51K | Purchase |
VITT DANIEL |
Chief Executive Officer | 391.88K | Purchase |
WHALEY GLENN |
Chief Financial Officer | 95.51K | Purchase |
Fundamentals
Market cap$106.70M
Enterprise value$-47.83M
Revenue (TTM)—
Gross profit—
EBITDA$-117.73M
Net income$-111.57M
EPS (TTM)$-3.83
Free cash flow$-51.41M
Total cash$155.10M
Total debt$567.00K
Book value / share$9.35
Shares outstanding13.64M
Float12.01M
Short % of float13.92%
Dividend yield0.00%
Beta (5Y)1.45
Valuation & profitability ratios
Trailing P/E—
Forward P/E-3.22
PEG ratio—
Price / sales—
Price / book0.84
EV / revenue—
EV / EBITDA0.41
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-138.17%
Return on assets-66.80%
Debt / equity0.44
Current ratio5.05
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $81.98M | $80.05M | $83.22M | $71.25M | +2.4% |
| Selling, general & admin | $21.25M | $18.01M | $16.01M | $15.26M | +18.0% |
| Total operating expense | $103.23M | $98.05M | $99.22M | $86.52M | +5.3% |
| Operating income | -$103.23M | -$98.05M | -$99.22M | -$86.52M | -5.3% |
| Net interest income | $1.04M | $3.39M | $3.08M | $1.04M | -69.3% |
| Pre-tax income | -$97.17M | -$100.51M | -$93.61M | -$120.41M | +3.3% |
| Net income | -$97.17M | -$100.51M | -$93.61M | -$120.41M | +3.3% |
| Net income to common | -$97.17M | -$100.51M | -$93.61M | -$120.41M | +3.3% |
| Basic EPS | -6.20 | -10.00 | -21.10 | -37.80 | +38.0% |
| Diluted EPS | -6.20 | -10.00 | -21.10 | -37.80 | +38.0% |
| EBIT | -$103.23M | -$98.05M | -$99.22M | -$86.52M | -5.3% |
| EBITDA | -$103.06M | -$97.92M | -$99.11M | -$86.44M | -5.3% |
| Basic shares | 15.57M | 10.02M | 4.43M | 3.18M | +55.4% |
| Diluted shares | 15.57M | 10.02M | 4.43M | 3.18M | +55.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $15.48M | $35.67M | $46.67M | $106.75M | — | -56.6% |
| Cash & short-term investments | $15.48M | $35.67M | $46.67M | $116.37M | — | -56.6% |
| Total current assets | $22.87M | $39.33M | $52.53M | $125.86M | — | -41.9% |
| Property, plant & equipment | $1.18M | $1.54M | $1.76M | $1.85M | — | -23.0% |
| Goodwill & intangibles | — | — | — | $0 | $32.97M | — |
| Total assets | $24.05M | $40.87M | $54.30M | $127.75M | — | -41.1% |
| Total current liabilities | $30.62M | $22.18M | $24.73M | $13.08M | — | +38.1% |
| Total debt | $577.00K | $1.00M | $1.33M | $1.56M | — | -42.5% |
| Total liabilities | $30.73M | $22.44M | $25.37M | $14.07M | — | +36.9% |
| Retained earnings | -$608.57M | -$511.40M | -$410.89M | -$317.28M | — | -19.0% |
| Shareholder equity | -$6.67M | $18.43M | $28.93M | $113.68M | — | -136.2% |
| Working capital | -$7.75M | $17.16M | $27.80M | $112.79M | — | -145.2% |
| Net tangible assets | -$6.67M | $18.43M | $28.93M | $113.68M | — | -136.2% |
| Shares issued | 12.04M | 9.02M | 4.52M | 3.93M | — | +33.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$97.17M | -$100.51M | -$93.61M | -$120.41M | +3.3% |
| Depreciation & amortisation | $168.00K | $134.00K | $111.00K | $77.00K | +25.4% |
| Stock-based compensation | $8.86M | $8.53M | $7.10M | $7.93M | +3.9% |
| Change in working capital | $1.84M | $330.00K | $15.05M | $9.53M | +457.0% |
| Operating cash flow | -$85.81M | -$84.77M | -$70.83M | -$65.14M | -1.2% |
| Capital expenditure | -$161.00K | -$264.00K | -$334.00K | -$112.00K | +39.0% |
| Investing cash flow | -$161.00K | -$264.00K | $9.46M | -$9.74M | +39.0% |
| Financing cash flow | $65.58M | $74.54M | $1.03M | $95.76M | -12.0% |
| Free cash flow | -$85.97M | -$85.03M | -$71.16M | -$65.26M | -1.1% |
| End cash position | $15.48M | $35.67M | $46.67M | $106.75M | -56.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Research & development | $25.93M | $25.63M | $19.07M | $20.01M | $21.37M | — | +1.2% |
| Selling, general & admin | $9.40M | $7.61M | $4.26M | $5.98M | $5.71M | — | +23.5% |
| Total operating expense | $35.33M | $33.23M | $23.33M | $25.99M | $27.08M | — | +6.3% |
| Operating income | -$35.33M | -$33.23M | -$23.33M | -$25.99M | -$27.08M | — | -6.3% |
| Net interest income | $1.29M | $760.00K | $197.00K | $419.00K | $241.00K | — | +69.2% |
| Pre-tax income | -$34.10M | -$32.59M | -$19.30M | -$25.58M | -$26.82M | — | -4.6% |
| Net income | -$34.10M | -$32.59M | -$19.30M | -$25.58M | -$26.82M | — | -4.6% |
| Net income to common | -$34.10M | -$32.59M | -$19.30M | -$25.58M | -$26.82M | — | -4.6% |
| Basic EPS | -0.80 | -1.08 | — | -1.30 | -2.03 | -2.51 | +25.9% |
| Diluted EPS | -0.80 | -1.08 | — | -1.30 | -2.03 | -2.51 | +25.9% |
| EBIT | -$35.33M | -$33.23M | -$23.33M | -$25.99M | -$27.08M | — | -6.3% |
| EBITDA | -$35.29M | -$33.20M | -$23.29M | -$25.95M | -$27.04M | — | -6.3% |
| Basic shares | 42.51M | 30.14M | — | 19.39M | 13.22M | 10.13M | +41.1% |
| Diluted shares | 42.51M | 30.14M | — | 19.39M | 13.22M | 10.13M | +41.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $155.10M | $186.63M | $15.48M | $35.13M | $55.31M | -16.9% |
| Cash & short-term investments | $155.10M | $186.63M | $15.48M | $35.13M | $55.31M | -16.9% |
| Total current assets | $157.83M | $188.76M | $22.87M | $39.27M | $59.84M | -16.4% |
| Property, plant & equipment | $1.34M | $983.00K | $1.18M | $1.43M | $1.59M | +35.9% |
| Total assets | $159.17M | $189.74M | $24.05M | $40.70M | $61.43M | -16.1% |
| Total current liabilities | $31.26M | $38.36M | $30.62M | $30.08M | $27.31M | -18.5% |
| Total debt | $567.00K | $421.00K | $577.00K | $792.00K | $979.00K | +34.7% |
| Total liabilities | $31.59M | $38.51M | $30.73M | $30.20M | $27.52M | -18.0% |
| Retained earnings | -$675.26M | -$641.16M | -$608.57M | -$589.27M | -$563.69M | -5.3% |
| Shareholder equity | $127.58M | $151.23M | -$6.67M | $10.50M | $33.91M | -15.6% |
| Working capital | $126.57M | $150.40M | -$7.75M | $9.19M | $32.53M | -15.8% |
| Net tangible assets | $127.58M | $151.23M | -$6.67M | $10.50M | $33.91M | -15.6% |
| Shares issued | 13.64M | 13.62M | 12.04M | 9.87M | 9.87M | +0.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$34.10M | -$32.59M | -$19.30M | -$25.58M | -$26.82M | -4.6% |
| Depreciation & amortisation | $34.00K | $33.00K | $42.00K | $40.00K | $43.00K | +3.0% |
| Stock-based compensation | $6.78M | $4.47M | $1.31M | $3.61M | $1.90M | +51.9% |
| Change in working capital | -$3.92M | $10.64M | -$1.67M | $1.74M | $214.00K | -136.9% |
| Operating cash flow | -$31.00M | -$17.30M | -$19.28M | -$20.14M | -$24.61M | -79.2% |
| Capital expenditure | -$249.00K | -$2.00K | -$11.00K | -$67.00K | -$36.00K | -12,350.0% |
| Investing cash flow | -$249.00K | -$2.00K | -$11.00K | -$67.00K | -$36.00K | -12,350.0% |
| Financing cash flow | $118.00K | $188.64M | $59.00K | $0 | $65.52M | -99.9% |
| Free cash flow | -$31.25M | -$17.30M | -$19.29M | -$20.21M | -$24.64M | -80.6% |
| End cash position | $155.10M | $186.63M | $15.48M | $35.13M | $55.31M | -16.9% |
Options analytics
Put / call volume
0.83
Call-heavy session
Put / call open interest
0.22
Positioning, not flow
Max pain
1.00
-87.2% from spot
ATM implied vol
0.0%
Nearest strike to spot
Skew (10% OTM)
+6.2%
Puts bid over calls
Call volume
199
Contracts, this expiry
Put volume
166
Contracts, this expiry
Heaviest call OI
1.00
372 contracts
Heaviest put OI
1.00
127 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -1.17 | -0.80 | +31.3% |
| Mar 2026 | -0.96 | -1.08 | -12.8% |
| Dec 2025 | -1.11 | -0.70 | +37.0% |
| Sep 2025 | -1.77 | -1.30 | +26.4% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.96 | 11 | $0 | 0.0% |
| Next quarter | -0.82 | 11 | $0 | 0.0% |
| Current year | -3.57 | 11 | $0 | 0.0% |
| Next year | -2.43 | 10 | $0 | 0.0% |
Analyst targets & ownership
Mean target$43.09
High target$85.00
Low target$22.00
Implied upside426.14%
Analyst count11
ConsensusSTRONG BUY
Strong buy / Buy0 / 12
Hold0
Sell / Strong sell0 / 0
Held by insiders0.97%
Held by institutions71.18%
Institutions holding67
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
8.82
-7.19% from price
SMA 20
9.90
-21.03% from price
SMA 50
12.96
-39.65% from price
SMA 100
13.51
-39.38% from price
SMA 200
11.37
-31.24% from price
EMA 12
9.11
-10.08% from price
EMA 26
10.57
-22.51% from price
EMA 50
11.90
-31.16% from price
RSI (14)
23.2
Oversold
MACD (12,26,9)
-1.46
Hist -0.09
ATR (14)
0.70
8.94% of price
Realised vol 30D
71.0%
Annualised
Bollinger upper
12.40
20, 2σ
Bollinger lower
7.40
20, 2σ
50 / 200 cross
Golden
12.96 vs 11.37
Trend bias
Below 200
-31.24%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.50
More volatile than market
Correlation to SPY
0.24
Largely independent
Realised vol 30D
71.0%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-53.7%
Peak to trough
Max drawdown 5Y
-96.4%
Peak to trough
ATR 14
0.70
8.94% of price
Beta (reported)
1.45
5Y monthly, from filing
Short interest
Shares short
1.79M
Prior 1.28M
Change vs prior
+40.5%
Shorts adding
% of float
13.92%
Elevated
% of shares out
13.15%
Against total outstanding
Days to cover
6.5
Crowded exit
Float
12.01M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 10, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Sep 10, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 17, 26 | Wedbush | INITIATED | — | Outperform |
| May 22, 26 | B. Riley Securities | MAINTAINED | Buy | Buy |
| Apr 30, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Apr 17, 26 | Stifel | INITIATED | — | Buy |
| Apr 15, 26 | D. Boral Capital | DOWNGRADE | Buy | Hold |
| Mar 24, 26 | Guggenheim | INITIATED | — | Buy |
| Mar 2, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Feb 13, 26 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Feb 9, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jan 7, 26 | D. Boral Capital | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay dateApr 15, 2019
Last split1:10
Split dateApr 27, 2026
SEC filings
Offering Registrations
S-8 · 2026-10-01
Corporate Changes & Voting Matters
8-K · 2026-09-11
Corporate Changes & Voting Matters
8-K · 2026-09-09
Offering Registrations
S-8 · 2026-08-12
Periodic Financial Reports
10-Q · 2026-08-11
Corporate Changes & Voting Matters
8-K · 2026-07-14
Corporate Changes & Voting Matters
8-K · 2026-07-06
Corporate Changes & Voting Matters
8-K · 2026-06-29
Headlines
Immunic to host virtual relapsing MS R&D Day on September 9
Proactive · 35d ago
Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026
PR Newswire · 35d ago
Immunic appoints Chitrang Davé as chief data and digital officer
Proactive · 36d ago
Immunic Appoints Chitrang Davé as Chief Data and Digital Officer
PR Newswire · 36d ago
Can Immunic (IMUX) Climb 163.03% to Reach the Level Wall Street Analysts Expect?
Zacks · 55d ago
Immunic advances MS drug toward key Phase 3 data, expects results by year-end
Proactive · 57d ago
Immunic: Q2 Earnings Snapshot
Associated Press · 57d ago
Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update
PR Newswire · 57d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.